BiVictriX Therapeutics PLC
LSE:BVX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Shenzhen Yinghe Technology Co Ltd
SZSE:300457
|
CN |
BiVictriX Therapeutics PLC
Other
BiVictriX Therapeutics PLC
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BiVictriX Therapeutics PLC
LSE:BVX
|
Other
-£82k
|
CAGR 3-Years
-60%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Other
£0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Other
$1k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Other
-£5.7m
|
CAGR 3-Years
-64%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-30%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Other
-£14.9m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
N/A
|
|
BiVictriX Therapeutics PLC
Glance View
BiVictriX Therapeutics Plc focuses on developing novel, highly-selective, bispecific ADCs to target unmet need in blood cancer. The company is headquartered in Alderley Edge, Cheshire and currently employs 5 full-time employees. The company went IPO on 2021-08-11. The firm has developed Bi-Cygni technology, which focuses on an area of unmet medical need. The firm utilizes Bi-Cygni therapeutics, which are designed to selectively target antigen co-expression fingerprints, or twin antigens, on tumour cells, which are absent from healthy cells. The firm has developed Bi-Cygni technology which utilizes Antibody Drug Conjugates, an existing class of potent biological drugs, for the treatment of various cancers including Acute Myeloid Leukaemia. The Company’s Bi-Cygni product candidate, BVX001, which is in early stage development for the treatment of acute myeloid leukaemia (AML). The firm has a diverse panel of cancer-specific twin antigens, across a range of cancer indications that include Diffuse Large B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm.
See Also
What is BiVictriX Therapeutics PLC's Other?
Other
-82k
GBP
Based on the financial report for Dec 31, 2023, BiVictriX Therapeutics PLC's Other amounts to -82k GBP.
What is BiVictriX Therapeutics PLC's Other growth rate?
Other CAGR 3Y
-60%
The average annual Other growth rates for BiVictriX Therapeutics PLC have been -60% over the past three years .
